Horizon Omics Biotechnology (Changchun) Co., Ltd. published the article "A First-in-Class Clinical G-Quadruplex-Targeting Drug: The Bench-to-Bedside Translation of the Fluoroquinolone QQ58 to CX-5461 (Pidnarulex)" in 2022. This article explains the mechanisms of action of CX-5461 (Pidnarulex) and its precursor structure QQ58 in relation to Topoisomerase II (TOP2) and G-quadruplexes (G4), as well as the latest research developments.
